Novo announced that the US FDA approved a growth hormone named Sogroya for new indications.
The drug is injected only once a week, meaning not every day, and it can now be used for children over 2.5 years old for certain “causes” of short stature, as well as for both children and adults with growth hormone deficiency.
In studies, it performed as well as daily injections.